AI Plays Tetris with Proteins

Pharma R&D efficiency is decreasing steadily, while the cost of new drug discovery is increasing exponentially. Vast amounts of structured data are being generated using high throughput technologies in drug discovery/development. However, the analysis and interpretation of this data for meaningful outcomes has been a challenge.

Peptris has developed a platform technology to enhance efficiencies across the drug discovery/development cascade using Artificial Intelligence/Machine Learning.

Peptris’ proprietary AI platform integrates unsupervised learning and generative AI to design optimized molecules, significantly reducing the need for wet lab testing. The automated platform streamlines this process, designing potent, safe, selective, and biologically active drug candidates. The platform has been used to discover Novel Chemical Entities (NCE), to repurpose or reposition approved drugs, and rescue molecules that have been proven safe in the clinic. We have a pipeline of preclinical assets that have been discovered, validated in vitro and in vivo disease models.

Peptris operates virtually, focusing on AI-driven discovery while outsourcing wet lab work to CROs and biotech partners. Revenue comes from licensing deals, milestone payments, and royalties, with partnerships across academia, biotech and pharma companies and rare disease organizations.